Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data

Lantern Pharma Inc.

Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.
Cash, equivalents, and marketable securities $79.6M at June 30, up from $19.2M Dec 31, 2020.
Preclinical data for LP-184 showed 93% avg tumor volume reduction in pancreatic cancer models.
Preparing LP-300 Phase 2 trial site selection and GMP batch for NSCLC in Q3 2021.
Reacquired LP-100 (Irofulven) rights from Allarity; $1M upfront plus up to $16M milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.